Fampridine-SR: A potassium-channel blocker for the improvement of walking ability in patients with MS
Date of Original Version
Fampridine-SR is a sustained-release oral medication that is pending FDA approval for the symptomatic treatment of multiple sclerosis (MS). Fampridine (4-aminopyridine) is a potassium-channel blocker that has been demonstrated to improve impulse conduction in nerve fibers in which myelin has been damaged, a hallmark of MS. Although fampridine-SR is not a disease-modifying therapy, this agent does offer a novel approach to target MS symptoms, specifically walking ability and lower-extremity strength. A recent phase 3 trial in patients with various types of MS demonstrated that fampridine-SR is associated with clinically meaningful improvements in some patients regardless of concomitant therapy. If approved by FDA, fampridine-SR would be the first drug specifically indicated for the improvement of walking ability in patients with MS.
Feret, Brett. "Fampridine-SR: A potassium-channel blocker for the improvement of walking ability in patients with MS." Formulary 44, 10 (2009): 293-299. https://digitalcommons.uri.edu/php_facpubs/1328